Response to letter to the editor: Letter by Chen et al. regarding article, “Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study”

Response to letter to the editor: Letter by Chen et al. regarding article, “Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study”

Saved in:

Bibliographic Details
Main Authors:	Mar Garcia – Zamora, Gemma García – Lluch, Lucrecia Moreno, Consuelo Cháfer – Pericás, Juan Pardo
Format:	Article
Language:	English
Published:	Elsevier 2025-05-01
Series:	Pharmacological Research
Subjects:	Alzheimer's disease Antidiabetic agents SGLT2 Insulins GLP1 Real-world study
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661825001264
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Response to letter to the editor: Expanding perspectives on the relationship between statin potency and lipophilicity in Alzheimer’s disease management
by: Mar Garcia–Zamora, et al.
Published: (2025-02-01)

¿Combinamos AR-GLP1 + i-SGLT2? Sí o no
by: Claudia Folino
Published: (2024-10-01)

The Role of Antidiabetic Drugs in Bone Health: Assessing the Risk of Osteoporosis Subtypes and Fractures Using Mendelian Randomization
by: Deng G, et al.
Published: (2025-04-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice
by: Gašper Tonin, et al.
Published: (2025-07-01)

The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
by: Alan J. Sinclair, et al.
Published: (2025-01-01)

Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes
by: Shubham Agarwal, et al.
Published: (2025-05-01)

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
by: Selim Aydemir, et al.
Published: (2024-12-01)

Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis
by: Yao Wang, et al.
Published: (2025-08-01)

The Effect of Frailty on Body Composition and Its Impact on the Use of SGLT-2 Inhibitors and GLP-1RA in Older Persons with Diabetes
by: Alan Sinclair, et al.
Published: (2025-06-01)

The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
by: Diego Rivas‐Otero, et al.
Published: (2025-03-01)

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01)

Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
by: Jingyi Guo, et al.
Published: (2025-03-01)

The relationship between antidiabetic and renal cancer: a systematic review
by: Shadman Newaz, et al.
Published: (2025-06-01)

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-08-01)

Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system
by: Demetria M. Bolden, et al.
Published: (2025-06-01)

Novel antidiabetic therapies in patients with peripheral artery disease: current perspective
by: Miodrag Janić, et al.
Published: (2024-11-01)

The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
by: Ping-Tao Tseng, et al.
Published: (2025-04-01)

The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
by: Xiangling Duan, et al.
Published: (2025-04-01)

Prescribing Antidiabetic Medications Among GPs in Croatia—A Real-Life Cross-Sectional Study
by: Tomislav Kurevija, et al.
Published: (2025-06-01)

Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors
by: Jiann-Jy Chen, et al.
Published: (2025-05-01)

ANTIDIABETIC ACTIVITY OF GUANIDINIUM SALT 2-AMINOPHENYLACETATE
by: E. V. Ponomarenko
Published: (2019-01-01)

Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
by: Christodoulos Dolapsakis, et al.
Published: (2025-01-01)

Barriers in prescribing antidiabetic medications with cardiovascular benefits: practice, experience, and attitudes of GPs in Croatia
by: Tomislav Kurevija, et al.
Published: (2025-05-01)

Comparing Out-of-Pocket Costs and Health-Related Quality of Life Between Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes
by: Hu S, et al.
Published: (2025-04-01)

Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs
by: Huize Gao, et al.
Published: (2025-06-01)

Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials
by: Kannan Sridharan, et al.
Published: (2025-05-01)

Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery
by: Ashley Wang, et al.
Published: (2025-03-01)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
by: Stefan D. Anker
Published: (2019-12-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors
by: Cian Sutcliffe, et al.
Published: (2025-05-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

Synergy of pharmacotherapy and physical activity in the treatment of obesity and cardiovascular prevention in patients with type 2 diabetes
by: Karolina Mędrysa, et al.
Published: (2025-06-01)

Timing and Adherence Matter for Sodium–Glucose Cotransporter‐2 Inhibitors in Heart Failure
by: Mehmet Birhan Yilmaz, et al.
Published: (2025-04-01)

Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental?
by: Azeez Taoreed Adegoke, et al.
Published: (2021-08-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)